What the 19,000-procedure record actually means

Over 19,000 ChondroFiller procedures have been performed globally since the product received its CE mark in 2013 — a figure that had passed 20,000 across more than a decade of commercial use by the time the manufacturer's Version 09 Clinical Evaluation Report (CER) was issued in April 2025. For a patient weighing up whether a relatively new injectable treatment is safe in practice, that volume provides a real-world tolerability signal that no single clinical trial could generate in the same timeframe.

The figures originate from post-market clinical follow-up (PMCF) and surveillance data synthesised within that CER — not from one large placebo-controlled trial. Across the published clinical studies in the programme, the reported complication rate for ChondroFiller liquid is approximately 0%, with a reoperation rate of 3–8%.

Two things are worth holding in mind together. First, the 19,000+ count reflects global commercial use across multiple joints and multiple centres; it is not exclusively knee-focused. Second, ChondroFiller liquid is classified as a CE-marked Class III medical device — the most stringently regulated implantable category under EU MDR — and the CER undergoes regulatory scrutiny as a condition of that classification. The headline safety figures carry weight, but they represent a manufacturer-compiled observational dataset rather than an independently run controlled study, a distinction that the sections below address directly.

How ChondroFiller works as a knee injection

The product itself is a liquid Type I collagen — the same structural protein that forms the framework of healthy cartilage. Because it is acellular, there are no live donor cells in the syringe: no biopsy is taken from a donor, and the body has no allogenic material to reject. The collagen is isolated from rat-tail tendon using a non-enzymatic, weak-acid extraction process that preserves telopeptides — the molecular anchors responsible for natural cross-linking. This matters because telopeptide-intact collagen can self-assemble in a physiologically authentic way once inside the joint, rather than behaving as a chemically altered foreign protein.

When injected, the liquid fills the cartilage defect and gels in situ within three to five minutes, conforming to the contours of the damaged surface without requiring fibrin glue or any bone drilling. The result is a dimensionally stable scaffold embedded in the joint.

The mechanism is acellular matrix-induced chondrogenesis: the scaffold acts as a structured invitation for the patient's own progenitor cells — migrating from the synovium and surrounding tissue — to populate the matrix and support the body's own repair processes. This is distinct from hyaluronic acid, which works as a lubricant and is cleared within weeks without providing a structural substrate for repair.

In the current clinical pathway at Lincolnshire Knee, ChondroFiller is delivered as an ultrasound-guided outpatient injection under local anaesthesia — no operating theatre, no general anaesthetic, no surgical incision.

How ChondroFiller complication rates compare

Placing the reported rates alongside the published figures for established surgical alternatives gives the clearest sense of where ChondroFiller sits on the risk spectrum. The manufacturer's April 2025 CER records an approximately 0% complication rate across ChondroFiller liquid studies — against a complication rate of up to 17% reported for autologous chondrocyte implantation and MACI procedures, and 0–7% for microfracture. The reoperation picture is similarly marked: 3–8% for ChondroFiller versus up to 37% for ACI/MACI and up to 41% for microfracture in published literature.

These differences are not arbitrary. Several structural features of the ChondroFiller pathway reduce the conditions under which complications typically arise. No bone is violated during the procedure — microfracture, by design, penetrates the subchondral plate, opening a pathway for fat-embolism and disrupting the bone architecture that underpins cartilage repair. Because the current pathway is an outpatient ultrasound-guided injection under local anaesthesia, the risks associated with general or spinal anaesthesia are not in play. And because the product is acellular, there is no donor-cell viability window to manage and no allogenic rejection cascade to guard against.

One important caveat applies to all of these comparisons: they draw on different study designs across different centres rather than head-to-head randomised controlled trial data. The numbers are meaningful, but they reflect observational cross-study benchmarking rather than a controlled like-for-like comparison.

Knee outcome scores from clinical studies

Clinical outcome data for ChondroFiller in the knee centres on two validated measures. The IKDC (International Knee Documentation Committee) score runs from 0 to 100, with higher scores reflecting better knee function — it is the standard patient-reported outcome used across cartilage repair research. MOCART is an MRI-based scoring system that quantifies how completely a defect has filled with repair tissue and how well that tissue integrates with the surrounding native cartilage.

Across four separate clinical datasets focused on focal knee cartilage defects, IKDC scores improved by approximately 30 points following ChondroFiller treatment. The threshold that defines a change worth calling clinically meaningful — the minimal clinically important difference (MCID) — sits at 16.7 points; a 30-point gain clears it by a substantial margin. The most detailed of these datasets is the prospective post-market clinical follow-up (PMCF) study by Jerosch et al., which recorded a mean IKDC improvement of 32.4 points, with patients reaching a functional score of approximately 80. Critically, that result held — and slightly increased — at the three-year mark, making it the longest available follow-up in the knee clinical programme.

On MRI, European studies report MOCART scores of 81.6–84.3, indicating more than 80% defect filling and good integration with surrounding cartilage. One study captured the timeline of repair: MOCART 65.3 at four weeks, rising to 81.6 at one year — a trajectory consistent with ongoing scaffold maturation rather than a static fill.

The consistency of direction and magnitude across four independent datasets carries weight even without a randomised controlled trial. These are observational study findings, not RCT-level evidence, and that distinction matters — but four studies pointing the same way is a more reliable signal than any single result in isolation.

Which knee patients are most likely to benefit

Suitability for ChondroFiller depends less on age and more on the character of the damage inside the joint. The treatment targets focal chondral defects — areas of cartilage loss up to roughly 6 cm², approximately the size of a thumbnail — affecting isolated Grade III or IV lesions where the cartilage surrounding the defect remains reasonably intact. That profile covers both post-traumatic injuries in younger, active patients and the discrete wear patches that can develop in the earlier stages of degenerative joint disease.

The ultrasound-guided injection pathway also suits patients with broader early-to-moderate degenerative wear who are not appropriate candidates for arthroscopic surgery, or who would prefer to avoid it. There is no fixed age ceiling.

End-stage osteoarthritis with global bone-on-bone loss across the joint is outside the indicated scope. ChondroFiller is an acellular scaffold designed to support focal repair; it is not a substitute for joint replacement where the articular surface has been comprehensively lost.

Several factors shape individual suitability: defect size, location on the joint surface, the quality of surrounding cartilage, body weight, lower-limb alignment, and the overall degree of OA progression. None of these can be assessed reliably from symptoms alone. Imaging — and a clinical review that considers the knee as a whole — is necessary before a treatment decision can be reached.

At Lincolnshire Knee, onMRI™ AI-assisted analysis of knee MRI, including cartilage segmentation and T2 mapping, can contribute useful structural detail to that assessment — and the same consultation is the appropriate moment to discuss where injectable scaffold therapy sits alongside other available options.

Reading the evidence before deciding

The evidence for ChondroFiller derives from manufacturer-sponsored post-market clinical follow-up (PMCF) studies and the manufacturer's own Clinical Evaluation Report — a regulatory-compliant standard for a CE-marked Class III device, but not equivalent to an independent randomised controlled trial. PMCF observational data across more than 19,000 procedures can demonstrate an absence of serious adverse events at scale; it cannot establish cause-and-effect safety with the rigour an RCT would provide. State that once, clearly, and it remains true without needing to be restated.

For a patient weighing a decision, the more useful frame is what the collective evidence does support. Four knee datasets pointing in the same direction — IKDC gains consistently exceeding the 16.7-point clinical significance threshold, three-year durability confirmed in Jerosch et al., MOCART scores above 81 — is a more reliable signal than any single study alone. Those numbers offer a realistic target: meaningful, MRI-confirmed functional improvement that holds over the medium term in appropriately selected patients.

What a consultant assessment can answer, and the published evidence cannot, are the questions specific to your joint: whether your defect size, location, and surrounding cartilage quality fall within the indicated range; what outcome trajectory is realistic for your particular findings; and how injectable scaffold therapy compares with surgical alternatives given your imaging and daily-life priorities.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.